EASL 2013: Triple Therapy for Hepatitis C Is Effective after Liver Transplantation but Comes with Side Effects
- Details
- Category: HCV Treatment
- Created on Friday, 10 May 2013 00:00
Adding the approved HCV protease inhibitor telaprevir (Incivek or Incivo) to pegylated interferon and ribavirin can increase sustained response rates even for difficult-to-treat liver transplant recipients, but adverse events are common, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
EASL 2013: Vaniprevir Boosts Interferon/Ribavirin Response Rate for Prior Non-Responders with Cirrhosis
- Details
- Category: HCV Treatment
- Created on Wednesday, 08 May 2013 00:00
The next-generation HCV protease inhibitor vaniprevir (MK-7009) increased post-treatment sustained response rates for previously treated genotype 1 chronic hepatitis C patients with liver cirrhosis when added to pegylated interferon plus ribavirin, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
EASL 2013: HCV Protease Inhibitor Simeprevir Pushes Triple Therapy Cure Rate Up to 80%
- Details
- Category: HCV Treatment
- Created on Friday, 03 May 2013 00:00
A second-generation HCV protease inhibitor, simeprevir (formerly TMC435), cured around 80% of previously untreated people with genotype 1 hepatitis C infection when combined with pegylated interferon and ribavirin, Michael Manns of the University of Hannover Medical School reported last week at the EASL International Liver Congress (EASL 2013) in Amsterdam. Overall, 91% of simeprevir-treated patients able to stop all treatment after 24 weeks.
EASL 2013: Compassionate Access to New Hepatitis C Drugs Is an 'Emergency' for European Patients
- Details
- Category: HCV Treatment
- Created on Friday, 03 May 2013 00:00
European governments must move quickly to ensure that compassionate use arrangements are put into place to allow access to new hepatitis C drugs for people with cirrhosis, advocates and doctors said at the EASL International Liver Congress (EASL 2013) in Amsterdam last week. However, clear differences in opinion emerged between patients and doctors regarding who should make decisions about acceptable levels of risk to patients during a symposium on compassionate use organized by the European Liver Patients Association.
EASL 2013: Daclatasvir plus Interferon Cures More Genotype 2/3 Hepatitis C Patients
- Details
- Category: HCV Treatment
- Created on Friday, 03 May 2013 00:00
Adding the HCV NS5A inhibitor daclatasvir to pegylated interferon and ribavirin for 12 or 16 weeks led to higher response rates for previously untreated people with genotype 2 or 3 hepatitis C, according to results from the COMMAND study reported last week at the EASL International Liver Congress(EASL 2013) in Amsterdam. People with genotype 3, however, did not respond as well as those with genotype 2.
More Articles...
- EASL 2013: Sofosbuvir + Interferon/Ribavirin Cures 90% of People with Hard-to-Treat HCV Genotypes
- EASL 2013: Daclatasvir + Asunaprevir + BMS-791352 Looks Promising as Interferon-free Combo
- EASL 2013: Triple-Drug HCV Therapy Comes with High Risk of Serious Adverse Events for Cirrhotics
- EASL 2013: Hep C Quad Regimens Quashed, but Some Components Go Forward
- EASL 2013: Second-generation Protease Inhibitor Faldaprevir Cures up to 80% of Genotype 1 Hepatitis C
- EASL 2013: Daclatasvir + Sofosbuvir Offers Rescue Therapy after Current Standard of Care
- EASL 2013: MK-5172 Boosts Interferon/Ribavirin Response Regardless of IL28B Status
- EASL 2013: Sofosbuvir + Ribavirin Cures Most Genotype 2 Hepatitis C, but Genotype 3 Response Is Lower
- EASL 2013: AbbVie Interferon-free Combination Cures Over 90% of Hepatitis C Genotype 1
- EASL 2013: Probiotics May Help Manage Hepatic Encephalopathy in Patients with Cirrhosis
- EASL 2013: HIV/HCV Coinfected at Risk for Decompensation, May Need Prompt Treatment
Web Design and Development by